Conference Reports for NATAP

Targeting HIV Entry: 3rd International Workshop Washington, DC December 7-9, 2007 Back

Characterization of Maraviroc Resistance in Patients Failing Treatment with CCR5-Tropic Virus in MOTIVATE 1 and 2       Reported by Jules Levin 3rd International Workshop on Targeting HIV Entry Washington, DC, USA, December 7-8, 2007   Julie Mori1, Marilyn Lewis1, Paul Simpson1, Jeannette Whitcomb2, Lynn McFadyen1, Phylinda Chan1 and Mike Westby1 1Pfizer Global Research and Development, Sandwich, UK; 2Monogram Biosciences, California, USA   Maraviroc Resistance: Author Summary of Clinical Findings Adequate exposure to maraviroc combined with a lack of active drugs in a patients OBT were the most likely reasons for the development of maraviroc resistance and subsequent treatment failure in four patients failing maraviroc-based therapy with CCR5-tropic virus --Maraviroc resistance was selected in those patients who had ≦1 active background drug in their treatment regimen --Maraviroc exposure was at the low end of the optimal exposure distribution